Buscar en
Revista Española de Medicina Nuclear e Imagen Molecular
Toda la web
Inicio Revista Española de Medicina Nuclear e Imagen Molecular Schwannomatosis/neurofibromatosis type 2 associated multiple schwannomas visuali...
Información de la revista
Vol. 32. Núm. 4.
Páginas 275-276 (Julio - Agosto 2013)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 32. Núm. 4.
Páginas 275-276 (Julio - Agosto 2013)
Interesting images
Acceso a texto completo
Schwannomatosis/neurofibromatosis type 2 associated multiple schwannomas visualized on FDG-PET/CT
Schwannomatosis/neurofibromatosis tipo 2 en FDG PET/TC de un paciente con múltiples schwannomas
Visitas
1798
V. Beylergil
Autor para correspondencia
beylergv@mskcc.org

Corresponding author.
, S. Haque, A. Carver, M.H. Bilsky, J.A. Carrasquillo
Memorial Sloan Kettering Cancer Center, New York, United States
Este artículo ha recibido
Información del artículo
Texto completo
Bibliografía
Descargar PDF
Estadísticas
Figuras (2)
Texto completo

We present a patient with neurocutaneous syndrome, status prior resections for cervical schwannomas and median as well as radial nerve schwannomas. This is a 57-year-old female with neurocutaneous syndrome presenting at 42 years of age with unilateral vestibular schwannoma. Genetic testing was negative but on clinical criteria neurofibromatosis-2 (NF-2) or schwannomatosis were considered.1 She underwent FDG PET/CT 85min after intravenous injection of 11.3mCi (418.1MBq) FDG, for recent onset of severe left back pain with suspected cauda equina compression. Whole-body FDG PET/CT showed multiple FDG avid soft tissue foci overlying the sciatic nerve, consistent with multiple schwannomas (Fig. 1). It also demonstrated heterogenous uptake corresponding to multiple lesions visualized on MRI (Fig. 2).

Fig. 1.

Whole-body FDG PET/CT showed (A–C) a series of FDG avid lesions overlying the left sciatic nerve (arrows) confirmed on MRI measuring up to 2.7cm×2.2cm and SUVmax whole body weight of 3.3, 3.2 and 3.1. In addition, hypermetabolic lesions were seen in left axilla and right shoulder (SUVmax of. 4.6 and 4.3, respectively), consistent with schwannomas on MRI (data not shown).

(0,14MB).
Fig. 2.

FDG PET/CT also showed heterogenous uptake in the spinal canal (SUV 4.1) (A–C) that corresponded to additional lesions (arrows) on T1 contrast MRI (D).

(0,26MB).

Schwannomatosis can be hard to differentiate from NF-2 and some authors suggested that vestibular schwannomas utilized in the Manchester criteria,1 should not be an exclusion criterion for the diagnosis of schwannomatosis. NF-2 is a rare autosomal dominant syndrome that may have MERLIN gene mutation and/or characterized by vestibular schwannomas, and other schwannomas, multiple meningiomas, ependymoma and lens opacities. Neurofibromatosis type 1 (NF-1), on the other hand, is a different disease with a few overlapping features.1 In contrast to NF-2 where malignant transformation is rare, NF-1 has 10% cumulative incidence of malignant transformation2 thus several reports have described the use of FDG in NF-1 to differentiate between benign peripheral nerve sheath tumors (PNST) and malignant PNST.

Our report is unique in showing histologically proven intra spinal canal schwannomas associated with neurocutaneous syndrome related to NF-2 or schwannomatosis. FDG uptake was in the range described for benign PNST and some malignant PNST. In our patient, given that there are multiple sites with same intensity of FDG uptake malignant transformation of any lesion was unlikely. This rare case also illustrates why close attention should be paid to the spinal canal (Fig. 2A–D) in these patients, since these lesions can easily be mistaken for physiologic uptake in the distal spinal cord. Furthermore FDG may detect other sites of schwannomas, as seen in this patient's sciatic nerve.

A single case report of FDG uptake in an intraspinal canal schwannoma has been reported.3

Because these lesions were consistent with her pain distribution, she underwent T11-L2 partial laminectomy and removal of histologically confirmed benign intradural schwannomas, with resolution of pain symptoms.

References
[1]
E.J. Uhlmann, S.R. Plotkin.
Neurofibromatoses.
Adv Exp Med Biol, 724 (2012), pp. 266-277
[2]
R.E. Ferner, J.F. Golding, M. Smith, E. Calonje, W. Jan, V. Sanjayanathan, et al.
[F-18]2-fluoro-2-deoxy-d-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study.
Ann Oncol, 19 (2008), pp. 390-394
[3]
J.M. Wilmshurst, S.F. Barrington, D. Pritchard, T. Cox, P. Bullock, M. Maisey, et al.
Positron emission tomography in imaging spinal cord tumors.
J Child Neurol, 15 (2000), pp. 465-472
Copyright © 2013. Elsevier España, S.L. and SEMNIM
Opciones de artículo
Herramientas
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos